Purchase this article with an account.
Edmund Tsui, Sivakumar Rathinam, Radhika Thundikandy, Anuradha Kanakath, S Balamurugan, R Vedhanayaki, Lyndell L Lim, Eric B Suhler, Hassan Aldhibi, John Alexander Gonzales, Thuy Doan, Jeremy Keenan, Caleb Ebert, Eric Kim, Travis C Porco, Nisha Acharya; Evaluation of uveitic macular edema in the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Trial. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3856.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The First-line Antimetabolite as Steroid-sparing Treatment (FAST) Trial is a randomized comparative effectiveness trial to determine which treatment, methotrexate (MTX) 25mg once weekly or mycophenolate mofetil (MMF) 1.5g twice daily, is more effective as first-line corticosteroid-sparing treatment for patients with non-infectious intermediate, posterior, or panuveitis. As part of the FAST Trial, optical coherence tomography (OCT) imaging is obtained prospectively. We compare the outcomes of uveitic macular edema in the FAST Trial.
Patients were initiated on a standardized oral prednisone taper starting at 1 mg/kg and randomized to receive either oral MTX 25mg once weekly or oral MMF 1.5g twice daily. Patients underwent monthly clinical examinations and OCT imaging. OCT images were graded at the reading center for the presence or absence of macular edema. We included all patients with macular edema at baseline and excluded patients with a serous detachment in the setting of Vogt-Koyanagi-Harada (VKH) disease. Change in macular thickness and visual acuity (VA) between treatment groups was evaluated with a linear mixed effects model. The primary endpoint was 6 months.
Of the 216 patients enrolled in the FAST Trial, after excluding eyes with serous detachment with VKH disease, there were n=42 eyes in the MTX group and n=55 eyes in the MMF group with baseline macular edema. In these eyes, baseline median logMAR VA was 0.40 (Snellen equivalent 20/50) and 0.38 (20/48) for the MTX and MMF groups, respectively. Median change in logMAR VA was -0.10 and -0.16 for patients in MTX and MMF groups, respectively (P=0.04). Final median logMAR VA was 0.20 (20/32) for both groups. Baseline median central subfield macular thickness was 359μm in the MTX group and 342μm in the MMF group. At 6 months, the median macular thickness decreased to 330μm with MTX and 309μm with MMF. The change in macular thickness was not significantly different between the two groups (P=0.95). At 6 months, 8 (19.0%) eyes in the MTX and 22 (40.0%) eyes in MMF groups had resolution of macular edema (P=0.06).
In eyes with uveitic macular edema, treatment with either MTX or MMF results in a similar decrease in macular thickness and rate of resolution of macular edema. Visual acuity improved in patients treated with either MTX or MMF and had similar visual acuities at the 6-month primary endpoint.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
This PDF is available to Subscribers Only